X
<

What Drove Eli Lilly in 3Q17?

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 8
What Drove Eli Lilly in 3Q17? PART 8 OF 12

How Is Eli Lilly’s Neuroscience Portfolio Positioned after 3Q17?

Cymbalta revenue trends

In 3Q17, Eli Lilly’s (LLY) Cymbalta generated revenues of $183.2 million, a ~42% decline on a year-over-year (or YoY) basis and an ~11% decline on a quarter-over-quarter basis. In 3Q17, in the US and international markets (outside the US markets), Cymbalta reported revenues of $19.6 million and $163.5 million, respectively, compared to $162.3 million and $151.2 million in 3Q16.

Cymbalta reported revenues of $564.4 million compared to $748.7 million in YTD (year-to-date) September 2016 in the first nine months of 2017. $100.8 million of this came from US markets and $463.6 million came from US markets. Cymbalta is used to treat major depressive disorders.

How Is Eli Lilly’s Neuroscience Portfolio Positioned after 3Q17?

Interested in LLY? Don't miss the next report.

Receive e-mail alerts for new research on LLY

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Prozac revenue trends

In 3Q17, Prozac generated revenues of $35.3 million, a ~10% decline on a YoY basis and a 14% decline on a quarter-over-quarter basis. In 3Q17, in the US and international markets, Prozac generated revenues of $14.6 million and $20.7 million, respectively, compared to $17.8 million and $21.6 million in 3Q16.

Prozac reported YTD September 2017 revenues of $126.3 million. Prozac generated revenues of $62.7 million and $63.5 million from the US and international markets in the first nine months of 2017.

In the antidepressant drugs market, Cymbalta and Prozac’s competitors include Pfizer’s (PFE) Effexor and Zoloft, and Allergan’s (AGN) Lexapro and Viibryd. In 3Q17, Lexapro, Viibryd, and Effexor reported revenues of $12.9 million, $86.5 million, and $78 million, respectively.

Strattera revenue trends

In 3Q17, Strattera reported revenues of $137.1 million, which is a ~31% decline on a YoY basis and a 27% decline on a quarter-over-quarter basis. In 3Q17, in the US and international markets, Strattera generated revenues of $52.9 million and $84.1 million, respectively, compared to $119.5 million and $79.3 million in 3Q16.

Strattera reported YTD September 2017 revenues of $519.9 million. In the US and international markets, Strattera generated revenues of $276.9 million and $243.0 million, respectively, in the first nine months of 2017.

Strattera’s peers in the ADHD (attention deficit hyperactivity disorder) market include Johnson & Johnson’s (JNJ) Concreta, Novartis’s Ritalin, and others.

Zyprexa revenue trends

In 3Q17, Zyprexa generated revenues of $140.6 million, a ~6% decline on a YoY basis. In 3Q17, Zyprexa’s quarter-over-quarter revenues remained flat. Zyprexa reported YTD September 2017 revenues of $428.9 million. In the US and international markets, Zyprexa reported YTD September 2017 revenues of $49.3 million and $379.6 million, respectively.

The iShares Russell 1000 Growth ETF (IWF) invests ~0.58% of its total portfolio holding in Eli Lilly.

X

Please select a profession that best describes you: